Europe Plasmapheresis Machine Market Size, Share & Trends Analysis Report By Collection Type (Plasma Collection System, Multi-Component Collection System), By Technology (Centrifugation-Based Plasmapheresis, Membrane Filtration-Based Plasmapheresis, Others), By Application (Extracorporeal Therapy, Plasma Donation, Others), By End-User (Hospitals and Clinics, Blood Donation Centers, Research Institutes, Home Care Settings, Others) and By Country (U.K., Germany, France, Spain, Italy, Russia, Nordic, Benelux, Rest of Europ) Forecasts, 2026-2034

Europe Plasmapheresis Machine Market Size

The Europe plasmapheresis machine market size was valued at USD 0.44 billion in 2025 and is projected to grow from USD 0.47  billion in 2026 to reach USD 0.82 billion by 2034, growing at a CAGR of 7.10% during the forecast period 2026–2034.

A plasmapheresis machine is a device that extracts small volumes of blood at a time through plasmapheresis. Plasmapheresis is a procedure that involves taking blood, separating it into plasma and cells, and then returning the cells into circulation. It is done precisely to remove antibodies in the treatment of autoimmune diseases. Pheresis or apheresis is a procedure that removes blood, filters and keeps elements of it, and then restores the blood to the body. Platelets, red blood cells, white blood cells, and plasma can all be separated. During the therapy, a machine is utilised to remove small amounts of blood at a time.

There are two ways to separate the components of blood:

Centrifugation rotates the blood, splitting it into sections based on density.

Filtration: By passing the blood through a filter, the plasma is separated from the blood. During plasma exchange, the device will reject unhealthy plasma and replace it with healthy plasma from a donor. To replace harmful plasma, saline, albumin, or a combination of the two can be utilised.

Plasmapheresis/plasmapheresis therapy is a valuable therapeutic option for individuals with severe multiple myeloma who require supportive care and have renal control dysfunction. As a result, the usage of market items grows in tandem with the frequency of various diseases and maladies. According to the data, Western Europe had the highest number of cases of myeloma for both sexes in 2016–2018.

Segmental Analysis

The Europe plasmapheresis machine market size is segmented into type, application, end-user, and geographic segments.

Multicomponent Collection Systems (MCCS) is a form of the improved plasma collection system that catches various components of human blood during donation. It is commonly mixed with plasma and other components such as serum, RBCs, and leukocytes. Although some definitions determine multi-component collection as a technique that results in two different blood components, the vast majority of research publications written by scientists worldwide define multicomponent apheresis as a process that results in the collection of two or more identical or distinct blood components. These multicomponent collections typically use the same centrifugation procedures used for collecting each component individually under various circumstances.

Plasmapheresis is an extracorporeal therapy process because it involves the removal, treatment, return, and exchange of blood plasma/its components from and to the blood circulation. Extracorporeal refers to a medical procedure that is conducted outside of the body. The rising autoimmune disorders, such as thrombotic thrombocytopenic purpura, Goodpasture's syndrome, lupus, Guillain-Barre syndrome, myasthenia gravis, and other chronic illnesses, government reimbursement programs in developed countries, and rising demand for plasma-derived medicines are driving the growth of the extracorporeal therapy segment.

Due to the recent spike in the COVID-19 pandemic, the hospitals and clinics segment is likely to gain the most market share. This is primarily due to the increased frequency of therapeutic plasma exchange operations and increased plasma and blood component donations due to COVID-19 infection. Hospitals with in-house transfusion facilities are predicted to improve the most during the forecast period.

Request Customizationto receive a tailored report.

Speak to an Analystto discuss market opportunities.

Regional Analysis

In 2030, the Europe Plasmapheresis Machine Market is predicted to increase at a substantial rate, with a CAGR of 9.20%, reaching a total value of 552.16 million USD. Individuals with severe multiple myeloma who require supportive care and have renal control failure may benefit from plasmapheresis/plasmapheresis therapy. As a result, market item utilisation develops in lockstep with the prevalence of numerous diseases and ailments. Western Europe had the largest number of instances of myeloma for both sexes in 2016–2018, according to the data. The increasing prevalence of blood disorders is expected to boost the adoption of apheresis equipment across Europe. Blood-related diseases like sickle-cell anaemia, haemophilia, and others affect millions of people in the region.

The apheresis equipment industry in Germany is expected to increase rapidly. The presence of organisations such as the National Blood Centre and the German Red Cross Blood Transfusion Services, among others, tasked with collecting, storing, testing, and distributing blood, aids device adoption. These organisations seek to raise blood donor awareness and increase the number of blood transfusion procedures performed across the country. Furthermore, the expanding older population, which is more susceptible to blood-related illnesses, will boost the size of the German apheresis equipment market.

For the first time in almost 20 years, citizens in the United Kingdom were allowed to give blood plasma for medical purposes on April 7. The plasma, which will be used to make immunoglobulins, is being collected at 14 sites as part of a three-month experiment by NHS Blood and Transplant (NHSBT). For patients, this is a watershed moment. Immunoglobulin (antibody-based) therapy can save lives in people whose immune systems aren't performing properly due to genetic abnormalities or cancer treatment.

List of Key and Emerging Players in Europe Plasmapheresis Machine Market